

**Listing of claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-43. (Cancelled)

44. (Currently Amended) A method for providing an artificial chemotactic factor gradient *in vivo* comprising administering a composition comprising one or more chemotactic factor(s), wherein transient entrapment of antigen presenting cells is achieved.

45. (Previously Presented) The method of claim 44 wherein the composition further comprises a device.

46. (Previously Presented) The method of claim 44 wherein the chemotactic factor is a chemokine.

47. (Previously Presented) The method of claim 46 wherein the composition further comprises a device.

48. (Currently Amended) The method of claim 45 wherein the device is comprises ethylene-vinyl-acetate.

49-64. (Cancelled)

65. (Previously Presented) The method of claim 44, 45 or 133 wherein the chemotactic factor is selected from the group consisting of chemokines, nucleotides and neuropeptides.

NY02:470418.1

66. (Previously Presented) The method of claim 46, 47, 48 or 133 wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , RANTES, MCP-3, MIP-5, MCPs, TARC, MDC, MIP-3 $\alpha$ , IL-8, SDF-1, MIP-3 $\beta$  and SLC.

67. (Withdrawn) The method of claim 65 wherein the nucleotide is selected from the group consisting of ADP, UTP and UDP.

68. (Withdrawn) The method of claim 65 wherein the neuropeptide is selected from the group consisting of calcitonin-related gene protein and  $\alpha$ - melanocyte-stimulating hormone.

69. (Currently Amended) The method of claim 66 wherein the chemokine is MIP-3 $\beta$ .

70-120. (Cancelled)

121. (Previously Presented) The method of claim 44 and 45 wherein the composition is administered subcutaneously.

122-132. (Cancelled)

133. (Previously Presented) The method of claim 47 wherein the device is ethylene-vinyl-acetate.